Eli Lilly & Co., a world-leading and global pharmaceutical company headquartered in Indianapolis in the state of Indiana, revealed that it will pay $8 billion in cash for cancer drug specialists Loxo Oncology, marking the second-biggest pharmaceutical deal of the year so far, per The Street.
Per the same announcement, the deal will see Eli Lilly pay an amount of $235 per share of Loxo, an amount which, per the company’s closing stocks last Friday of $139.87, represents a premium of 68 percent. Both companies also stated that the deal should be closed by the time the first quarter of 2019 ends. It’s also not subject to any financing condition of any sort.
Jacob Van Naarden, Chief Operating Officer for Loxo Oncology, said, “We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need. We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase 2 to discovery, will continue to thrive in Lilly’s hands.”
Good news for both companies
After news of the deal started circulating, both companies saw their shares increase, with Eli Lilly’s going up by 0.7 percent while Loxo’s surged by up to 65.9 percent. Part of this surge can also be attributed to news that the deal would take the Stamford, Connecticut-based biotech’s market value past $7.1 billion, increasing stock prices up to $232.06.
Per Eli Lilly, the transaction with Loxo Oncology will definitely impact its recently announced 2019 earnings guidance. However, the company assured that it will be updating its investors when the company publishes fourth-quarter and full-year earnings come Feb. 13.
Boosts and earnings
Thanks in part to stronger demand for new medicines and its leading drug franchise for diabetes, Eli Lilly was able to confidently boost its quarterly dividend and issued 2019 profits forecasts that can be observed as bigger than what the company previously expected.
The company expects its full-year 2019 earnings to be between $5.90 and $6.10 per share, and its next quarter dividend payout to rise by 15 percent to 64.5 cents per share. These numbers are higher than the previous one, which only goes up to $5.55 to $5.60 per share on a non-GAAP basis.
Furthermore, the company was also able to recently release Trulicity, a drug which can reduce the risk of major adverse cardiac instances in patients. With the new drug, the company was able to earn sales of $816.2 million, a number that is much stronger than what the company previously expected.
Stocks rise as zombie companies proliferate
Stocks are hitting new highs but the foundation underneath is degrading fast. The insane behavior of markets can be blamed...
Agricultural stock news every investor needs to know
The market has been short in Corn as farmers have been holding. That means that there is very little Corn...
3 tech investment sectors to capitalize on the 5G revolution
It's been clear that the size of the expected revolution that 5G will create is certain to be huge. For...
4 important biotech conferences to attend this year
2020 is full of events, and here are some of the most interesting biotech conferences every professional should consider: Bio€quity...
Crowdfunding rules are changing in Europe
Crowdfunding projects with up to $5.5 million (€5 million) are getting new regulations from the European Crowdfunding Service Providers (ECSP)....
- Crypto7 days ago
21 blockchain startups to compete at the European Blockchain Convention
- Business7 days ago
EssilorLuxottica is building an ambitious vision for 2020
- Africa7 days ago
Côte d’Ivoire and Ghana want to create a cocoa OPEC to support farmers
- Biotech7 days ago
German biotech companies continue to raise capital despite uncertainty